<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Psychiatry</journal-id><journal-title>BMC Psychiatry</journal-title><issn pub-type="epub">1471-244X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16120224</article-id><article-id pub-id-type="pmc">1208916</article-id><article-id pub-id-type="publisher-id">1471-244X-5-31</article-id><article-id pub-id-type="doi">10.1186/1471-244X-5-31</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Pharmacological challenge with a serotonin 1D agonist in alcohol dependence</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Vythilingum</surname><given-names>Bavanisha</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>bv@sun.ac.za</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Hugo</surname><given-names>Charmaine J</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>cjhugo@sun.ac.za</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Maritz</surname><given-names>J Stefan</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>stefan.maritz@mrc.ac.za</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Pienaar</surname><given-names>Willie</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>wppien@sun.ac.za</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Stein</surname><given-names>Dan J</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>djs2@sun.ac.za</email></contrib></contrib-group><aff id="I1"><label>1</label>MRC Unit on Anxiety and Stress Disorders, Dept of Psychiatry University of Stellenbosch, South Africa</aff><aff id="I2"><label>2</label>Dept of Psychiatry, University of Stellenbosch, South Africa</aff><aff id="I3"><label>3</label>Biostatistics Unit, Medical Research Council of South Africa</aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>24</day><month>8</month><year>2005</year></pub-date><volume>5</volume><fpage>31</fpage><lpage>31</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-244X/5/31"></ext-link><history><date date-type="received"><day>4</day><month>5</month><year>2005</year></date><date date-type="accepted"><day>24</day><month>8</month><year>2005</year></date></history><permissions><copyright-statement>Copyright © 2005 Vythilingum et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2005</copyright-year><copyright-holder>Vythilingum et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="3394" xml_f="3404" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3415" xml_f="3969" txt_i="22" txt_f="576">Both animal and clinical studies have implicated serotonergic dysfunction in the pathogenesis of alcohol abuse and dependence. However the exact mechanisms involved remain unknown. Theoretically, low serotonin promotes alcohol seeking behavior. Sumatriptan is a serotonin1D agonist. It is postulated that sumatriptan's agonism at this terminal autoreceptor increases negative feedback, creating a net effect of decreased serotonergic neurotransmission. Administration of sumatriptan should therefore produce a craving for alcohol and the desire to drink.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="4010" xml_f="4017" txt_i="578" txt_f="585">Methods</offsets></title><p><offsets xml_i="4028" xml_f="4279" txt_i="586" txt_f="837">Fifteen patients with alcohol dependence who had undergone detoxification were recruited. Sumatriptan (100 mg) and placebo was administered in cross-over fashion on 2 separate days 72 hours apart. Both patients and raters were blind to all treatments.</offsets></p><p><offsets xml_i="4286" xml_f="4622" txt_i="838" txt_f="1174">Patients were assessed on the following scales at -30, 0, 30, 90, 150 and 210 minutes: A 6-item scale designed to rate the patient's intention to drink; The Sensation Scale; a 13-item affect analog scale designed to rate the pattern and extent of emotional changes; and an 8-item scale designed to rate the patient's craving for alcohol</offsets></p></sec><sec><title><offsets xml_i="4644" xml_f="4651" txt_i="1176" txt_f="1183">Results</offsets></title><p><offsets xml_i="4662" xml_f="4792" txt_i="1184" txt_f="1314">No significant differences were found between the placebo and sumatriptan groups and no significant cross over effects were found.</offsets></p></sec><sec><title><offsets xml_i="4814" xml_f="4824" txt_i="1316" txt_f="1326">Conclusion</offsets></title><p><offsets xml_i="4835" xml_f="5034" txt_i="1327" txt_f="1526">The general lack of efficacy of sumatriptan in producing alcohol-like symptoms or a desire to drink alcohol may suggest that the 5HT1D receptor plays little role in the pathophysiology of alcoholism.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="5096" xml_f="5106" txt_i="1535" txt_f="1545">Background</offsets></title><p><offsets xml_i="5117" xml_f="5244" txt_i="1546" txt_f="1673">Both animal and clinical studies have implicated serotonergic dysfunction in the pathogenesis of alcohol abuse and dependence [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5275" xml_f="5276" txt_i="1673" txt_f="1674">1</offsets></xref><offsets xml_i="5283" xml_f="5284" txt_i="1674" txt_f="1675">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="5315" xml_f="5316" txt_i="1675" txt_f="1676">2</offsets></xref><offsets xml_i="5323" xml_f="5484" txt_i="1676" txt_f="1837">]. However the exact mechanisms involved remain unknown. Pharmacological challenge studies provide one way of identifying the specific receptor systems involved.</offsets></p><p><offsets xml_i="5491" xml_f="5590" txt_i="1838" txt_f="1937">Serotonergic dysfunction is thought particularly to be involved in alcohol craving. Verheul et al [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="5621" xml_f="5622" txt_i="1937" txt_f="1938">3</offsets></xref><offsets xml_i="5629" xml_f="5866" txt_i="1938" txt_f="2175">] proposed three types of craving – reward craving, relief craving and obsessive craving. Obsessive craving is defined as the loss of control over intrusive thoughts about alcohol and is believed to be mediated by a deficit of serotonin.</offsets></p><p><offsets xml_i="5873" xml_f="6109" txt_i="2176" txt_f="2412">m-chlorophenylpiperazine (m-CPP) is a serotonin agonist with actions at 5-HT1a, 5-HT1d, 5-HT2c receptors. The 5HT1a and 5HT1d receptors are autoreceptors and agonism here has been demonstrated to decrease net serotonergic transmission.[</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="6140" xml_f="6141" txt_i="2412" txt_f="2413">4</offsets></xref><offsets xml_i="6148" xml_f="6266" txt_i="2413" txt_f="2531">] m-CPP has been reported to elicit craving for alcohol and feelings similar to intoxication in abstinent alcoholics [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="6297" xml_f="6298" txt_i="2531" txt_f="2532">5</offsets></xref><offsets xml_i="6305" xml_f="6306" txt_i="2532" txt_f="2533">,</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="6337" xml_f="6338" txt_i="2533" txt_f="2534">6</offsets></xref><offsets xml_i="6345" xml_f="6525" txt_i="2534" txt_f="2714">]). This relates well to animal studies, where TFMPP administration (a compound structurally similar to mCPP) has discriminant stimulus properties similar to low doses of alcohol [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="6556" xml_f="6557" txt_i="2714" txt_f="2715">7</offsets></xref><offsets xml_i="6564" xml_f="6566" txt_i="2715" txt_f="2717">].</offsets></p><p><offsets xml_i="6573" xml_f="6833" txt_i="2718" txt_f="2978">Taken together, this suggests that alcohol may be used to self-medicate in patients with dysequilibrium of the serotonergic system. This hypothesis is given further support by studies showing the efficacy of serotonergic agents in the treatment of alcoholism [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="6864" xml_f="6865" txt_i="2978" txt_f="2979">8</offsets></xref><offsets xml_i="6872" xml_f="6873" txt_i="2979" txt_f="2980">-</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="6905" xml_f="6907" txt_i="2980" txt_f="2982">11</offsets></xref><offsets xml_i="6914" xml_f="7114" txt_i="2982" txt_f="3182">]. The serotonin system is, however, complex, and mCPP is a relatively nonselective agent. In order to delineate further the exact mechanisms involved in alcoholism more selective agents must be used.</offsets></p><p><offsets xml_i="7121" xml_f="7344" txt_i="3183" txt_f="3406">Sumatriptan is a selective serotonin(5HT)1D agonist. It is postulated that sumatriptan's agonism at this terminal autoreceptor increases negative feedback, creating a net effect of decreased serotonergic neurotransmission [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="7375" xml_f="7376" txt_i="3406" txt_f="3407">4</offsets></xref><offsets xml_i="7383" xml_f="7426" txt_i="3407" txt_f="3450">] In line with Verheul's model of craving [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="7457" xml_f="7458" txt_i="3450" txt_f="3451">3</offsets></xref><offsets xml_i="7465" xml_f="7583" txt_i="3451" txt_f="3569">] sumatriptan administration, by decreasing serotonergic transmission, should theoretically produce a desire to drink.</offsets></p><p><offsets xml_i="7590" xml_f="7973" txt_i="3570" txt_f="3953">Studies of sumatriptan administration in alcohol dependent patients suggest involvement of the 5HT1D receptor. Sumatriptan stimulates the release of growth hormone (GH) and inhibits the release of prolactin in normal individuals. In both long term and newly abstinent alcoholics sumatriptan administration did not increase GH secretion, suggesting alteration at the 5HT1D receptor. [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="8005" xml_f="8007" txt_i="3953" txt_f="3955">12</offsets></xref><offsets xml_i="8014" xml_f="8015" txt_i="3955" txt_f="3956">,</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="8047" xml_f="8049" txt_i="3956" txt_f="3958">13</offsets></xref><offsets xml_i="8056" xml_f="8057" txt_i="3958" txt_f="3959">]</offsets></p><p><offsets xml_i="8064" xml_f="8193" txt_i="3960" txt_f="4089">The 5HT1D receptor may also be associated with repetitive behaviours. In autism, increased GH response to sumatriptan was noted [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="8225" xml_f="8227" txt_i="4089" txt_f="4091">14</offsets></xref><offsets xml_i="8234" xml_f="8376" txt_i="4091" txt_f="4233">], with the severity of repetitive behaviours correlating with response. Addictive behaviours may be viewed as a type of repetitive behaviour.</offsets></p><p><offsets xml_i="8383" xml_f="8536" txt_i="4234" txt_f="4387">Furthermore, in OCD, sumatriptan has been suggested to produce similar effects to those of mCPP, and its administration led to exacerbation of symptoms [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="8568" xml_f="8570" txt_i="4387" txt_f="4389">15</offsets></xref><offsets xml_i="8577" xml_f="8963" txt_i="4389" txt_f="4775">], i.e loss of control over obsessive thoughts. We hypothesized that effects of sumatriptan would be similar to those of mCPP in patients with alcoholism, namely that administration of sumatriptan would potentiate obsessive craving for alcohol. Should this hypothesis be bourne out, it would point to specific involvement of the 5HT1d receptor in the pathophysiology of alcohol craving.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="9004" xml_f="9011" txt_i="4777" txt_f="4784">Methods</offsets></title><p><offsets xml_i="9022" xml_f="9540" txt_i="4785" txt_f="5303">Fifteen patients with alcohol dependence who had undergone detoxification (4 females and 11 males) were recruited from the acute detoxification units at Tygerberg and Stikland hospitals, Cape Town, South Africa. All subjects were medically stable, with no history of cardiac disorder, and with liver enzymes less than 1.5 times the maximum laboratory range at baseline. All subjects had at least seven alcohol and benzodiazepine-free days. For 72 hours prior to the challenge, subjects adhered to a tyramine-free diet.</offsets></p><p><offsets xml_i="9547" xml_f="10122" txt_i="5304" txt_f="5879">Informed written consent was obtained from all subjects and the ethics committee of the University of Stellenbosch approved the study. The research was carried out in accordance with the Declaration of Helsinki of the World Medical Association. During the study subjects were inpatients at the Alcohol Rehabilitation Unit at Stikland Hospital, and received ongoing psychotherapy. On completion of a 6 week program, subjects were discharged to a weekly outpatient therapy group. These measures were felt to be sufficiently containing to prevent experimentally induced relapse.</offsets></p><p><offsets xml_i="10129" xml_f="10442" txt_i="5880" txt_f="6193">Sumatriptan (100 mg) and placebo was administered orally in cross-over fashion on 2 separate days 72 hours apart. Sumatriptan was chosen as the challenge agent as it has the least side effects of the triptans. A drawback though, is that it has poor penetration of the blood brain barrier. However, previous work [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="10474" xml_f="10476" txt_i="6193" txt_f="6195">12</offsets></xref><offsets xml_i="10483" xml_f="10484" txt_i="6195" txt_f="6196">,</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="10516" xml_f="10518" txt_i="6196" txt_f="6198">13</offsets></xref><offsets xml_i="10525" xml_f="10908" txt_i="6198" txt_f="6581">] has showed altered hormonal responses in alcohol dependent patients, suggesting that sufficient amounts do cross over. Furthermore, in studies of OCD and related disorders, sumatriptan is the most commonly used challenge agent. The 100 mg dose was chosen as in previous work on OCD and OCD related disorders, 100 mg had been shown to increase obsessions and repetitive behaviours [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="10940" xml_f="10942" txt_i="6581" txt_f="6583">14</offsets></xref><offsets xml_i="10949" xml_f="10950" txt_i="6583" txt_f="6584">,</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="10982" xml_f="10984" txt_i="6584" txt_f="6586">15</offsets></xref><offsets xml_i="10991" xml_f="11047" txt_i="6586" txt_f="6642">] Both patients and raters were blind to all treatments.</offsets></p><p><offsets xml_i="11054" xml_f="11139" txt_i="6643" txt_f="6728">Patients were assessed on the following scales at -30, 0 30, 90, 150 and 210 minutes:</offsets></p><p><offsets xml_i="11146" xml_f="11231" txt_i="6729" txt_f="6814">1. A 6-item scale designed to rate the patient's intention to drink. (modified from [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="11262" xml_f="11263" txt_i="6814" txt_f="6815">6</offsets></xref><offsets xml_i="11270" xml_f="11446" txt_i="6815" txt_f="6991">]) Items were rated from 0 (not at all) to 4 (extremely), and included questions such as "I would like to drink alcohol" and "I intend to drink alcohol in the near future". A 6</offsets><sup><offsets xml_i="11451" xml_f="11454" txt_i="6991" txt_f="6994">th </offsets></sup><offsets xml_i="11460" xml_f="11543" txt_i="6994" txt_f="7077">question, "the tablet I took this morning feels similar to alcohol" was also posed.</offsets></p><p><offsets xml_i="11550" xml_f="11574" txt_i="7078" txt_f="7102">2. The Sensation Scale [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="11606" xml_f="11608" txt_i="7102" txt_f="7104">16</offsets></xref><offsets xml_i="11615" xml_f="11791" txt_i="7104" txt_f="7280">]. Items included side effects commonly produced by alcohol, such as nausea, facial flushing, dizziness and numbness. Items were rated from 0 (not at all) to 10 (a great deal).</offsets></p><p><offsets xml_i="11798" xml_f="11892" txt_i="7281" txt_f="7375">3. A 13-item affect analog scale designed to rate the pattern and extent of emotional changes[</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="11924" xml_f="11926" txt_i="7375" txt_f="7377">17</offsets></xref><offsets xml_i="11933" xml_f="11935" txt_i="7377" txt_f="7379">].</offsets></p><p><offsets xml_i="11942" xml_f="12102" txt_i="7380" txt_f="7540">4. An 8-item scale designed to rate the patient's craving for alcohol. Items included " I crave a drink right now" and "I want a drink so bad I can taste it". [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="12134" xml_f="12136" txt_i="7540" txt_f="7542">18</offsets></xref><offsets xml_i="12143" xml_f="12144" txt_i="7542" txt_f="7543">]</offsets></p><p><offsets xml_i="12151" xml_f="12326" txt_i="7544" txt_f="7719">Statistical analyses were carried on out the total score for each questionnaireas well specific variables of interest. For every variable the six sequential observed scores, y</offsets><sub><offsets xml_i="12331" xml_f="12332" txt_i="7719" txt_f="7720">1</offsets></sub><offsets xml_i="12338" xml_f="12342" txt_i="7720" txt_f="7724">...y</offsets><sub><offsets xml_i="12347" xml_f="12348" txt_i="7724" txt_f="7725">6</offsets></sub><offsets xml_i="12354" xml_f="12451" txt_i="7725" txt_f="7822">, of every subject on every occasion were summarized in two informative statistics, the sum S = y</offsets><sub><offsets xml_i="12456" xml_f="12457" txt_i="7822" txt_f="7823">1</offsets></sub><offsets xml_i="12463" xml_f="12465" txt_i="7823" txt_f="7825">+y</offsets><sub><offsets xml_i="12470" xml_f="12471" txt_i="7825" txt_f="7826">2</offsets></sub><offsets xml_i="12477" xml_f="12479" txt_i="7826" txt_f="7828">+y</offsets><sub><offsets xml_i="12484" xml_f="12485" txt_i="7828" txt_f="7829">3</offsets></sub><offsets xml_i="12491" xml_f="12493" txt_i="7829" txt_f="7831">+y</offsets><sub><offsets xml_i="12498" xml_f="12499" txt_i="7831" txt_f="7832">4</offsets></sub><offsets xml_i="12505" xml_f="12507" txt_i="7832" txt_f="7834">+y</offsets><sub><offsets xml_i="12512" xml_f="12513" txt_i="7834" txt_f="7835">5</offsets></sub><offsets xml_i="12519" xml_f="12521" txt_i="7835" txt_f="7837">+y</offsets><sub><offsets xml_i="12526" xml_f="12527" txt_i="7837" txt_f="7838">6</offsets></sub><offsets xml_i="12533" xml_f="12572" txt_i="7838" txt_f="7877">, and the linear trend contrast L = -8y</offsets><sub><offsets xml_i="12577" xml_f="12578" txt_i="7877" txt_f="7878">1</offsets></sub><offsets xml_i="12584" xml_f="12587" txt_i="7878" txt_f="7881">-5y</offsets><sub><offsets xml_i="12592" xml_f="12593" txt_i="7881" txt_f="7882">2</offsets></sub><offsets xml_i="12599" xml_f="12602" txt_i="7882" txt_f="7885">-2y</offsets><sub><offsets xml_i="12607" xml_f="12608" txt_i="7885" txt_f="7886">3</offsets></sub><offsets xml_i="12614" xml_f="12616" txt_i="7886" txt_f="7888">+y</offsets><sub><offsets xml_i="12621" xml_f="12622" txt_i="7888" txt_f="7889">4</offsets></sub><offsets xml_i="12628" xml_f="12631" txt_i="7889" txt_f="7892">+4y</offsets><sub><offsets xml_i="12636" xml_f="12637" txt_i="7892" txt_f="7893">5</offsets></sub><offsets xml_i="12643" xml_f="12647" txt_i="7893" txt_f="7897">+10y</offsets><sub><offsets xml_i="12652" xml_f="12653" txt_i="7897" txt_f="7898">6</offsets></sub><offsets xml_i="12659" xml_f="12812" txt_i="7898" txt_f="8051">. Note that the weights in the L contrast are obtained from the first order orthogonal polynomial for the unequally spaced time intervals of observation.</offsets></p><p><offsets xml_i="12819" xml_f="14038" txt_i="8052" txt_f="9271">Thus, for a particular variable every subject has two values of S one for sumatriptan and one for placebo,, say S1 and S2., and the drug effect is measured by S1-S2. The cross-over effect is measured by an estimate of the difference in location of the distribution of S1-S2 in the two groups; it can be mean(S1-S2, Group 1)-mean((S1-S2, Group2), or an estimate based on the Wilcoxon Rank Sum test; there are other possibilities, not used here. In the case of the mean the natural test statistic is of the form z = (difference of means)/(s.e. of the difference); note that the Welch version of the denominator was used in the calculation of z. The distribution of this statistic is "t" if the variable S1-S2 is normally distributed, with appropriate adjustment of the number of degrees of freedom for the Welch version of the ttest. In the present instance it is not, but being a difference of linear functions the distribution is symmetric, and significance levels given by the t-distribution are robust. However, in marginal cases exact significance levels for z was obtained from a permutation distribution. Further, in marginal cases the Wilcoxon Rank Sum test was used for confirmation, or otherwise, of the result.</offsets></p><p><offsets xml_i="14045" xml_f="14120" txt_i="9272" txt_f="9347">The linear effect scores, L, were analysed in the same way as the S scores.</offsets></p></sec><sec><title><offsets xml_i="14142" xml_f="14149" txt_i="9349" txt_f="9356">Results</offsets></title><p><offsets xml_i="14160" xml_f="14220" txt_i="9357" txt_f="9417">All but 2 measures showed no significant changes (See table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="14252" xml_f="14253" txt_i="9417" txt_f="9418">1</offsets></xref><offsets xml_i="14260" xml_f="14727" txt_i="9418" txt_f="9885">). On the variable "anxious" (item 8 of the affect analog scale) a significant cross over effect was found (z = -2.36, p = 0.046, df = 8; exact permutation P = 0.031; Wilcoxon Rank Sum test P = 0.023). In the group that received sumatriptan first the mean S1-S2 was negative, in the group that received placebo first it was positive. Neither mean differs clearly significantly from zero. In the placebo first group the signficance level attained was 0.08. (See table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="14759" xml_f="14760" txt_i="9885" txt_f="9886">2</offsets></xref><offsets xml_i="14767" xml_f="14768" txt_i="9886" txt_f="9887">)</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="14816" xml_f="14823" txt_i="9888" txt_f="9895">Table 1</offsets></label><table frame="hsides" rules="groups"><thead><tr><td></td><td></td><td align="center"><offsets xml_i="14916" xml_f="14921" txt_i="9897" txt_f="9902">Group</offsets></td><td align="center"><offsets xml_i="14945" xml_f="14946" txt_i="9903" txt_f="9904">N</offsets></td><td align="center"><offsets xml_i="14970" xml_f="14974" txt_i="9905" txt_f="9909">Mean</offsets></td><td align="center"><offsets xml_i="14998" xml_f="15005" txt_i="9910" txt_f="9917">SE Mean</offsets></td><td align="center"><offsets xml_i="15029" xml_f="15030" txt_i="9918" txt_f="9919">T</offsets></td><td align="center"><offsets xml_i="15054" xml_f="15055" txt_i="9920" txt_f="9921">p</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="15101" xml_f="15120" txt_i="9922" txt_f="9941">Affect analog Scale</offsets></td><td align="left"><offsets xml_i="15142" xml_f="15159" txt_i="9942" txt_f="9959">Cross-over effect</offsets></td><td align="left"><offsets xml_i="15181" xml_f="15194" txt_i="9960" txt_f="9973">Placebo first</offsets></td><td align="left"><offsets xml_i="15216" xml_f="15217" txt_i="9974" txt_f="9975">9</offsets></td><td align="left"><offsets xml_i="15239" xml_f="15242" txt_i="9976" txt_f="9979">0.0</offsets></td><td align="left"><offsets xml_i="15264" xml_f="15267" txt_i="9980" txt_f="9983">1.3</offsets></td><td align="right"><offsets xml_i="15290" xml_f="15296" txt_i="9984" txt_f="9990">-.1.25</offsets></td><td align="left"><offsets xml_i="15318" xml_f="15323" txt_i="9991" txt_f="9996">0.241</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="15372" xml_f="15389" txt_i="9999" txt_f="10016">Sumatriptan first</offsets></td><td align="left"><offsets xml_i="15411" xml_f="15412" txt_i="10017" txt_f="10018">6</offsets></td><td align="left"><offsets xml_i="15434" xml_f="15437" txt_i="10019" txt_f="10022">2.5</offsets></td><td align="left"><offsets xml_i="15459" xml_f="15462" txt_i="10023" txt_f="10026">1.5</offsets></td><td></td><td></td></tr><tr><td></td><td align="left"><offsets xml_i="15520" xml_f="15539" txt_i="10030" txt_f="10049">Linear Trend effect</offsets></td><td align="left"><offsets xml_i="15561" xml_f="15574" txt_i="10050" txt_f="10063">Placebo first</offsets></td><td align="left"><offsets xml_i="15596" xml_f="15597" txt_i="10064" txt_f="10065">9</offsets></td><td align="left"><offsets xml_i="15619" xml_f="15623" txt_i="10066" txt_f="10070">-3.7</offsets></td><td align="left"><offsets xml_i="15645" xml_f="15648" txt_i="10071" txt_f="10074">1.3</offsets></td><td align="left"><offsets xml_i="15670" xml_f="15675" txt_i="10075" txt_f="10080">-0.91</offsets></td><td align="left"><offsets xml_i="15697" xml_f="15702" txt_i="10081" txt_f="10086">0.391</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="15751" xml_f="15768" txt_i="10089" txt_f="10106">Sumatriptan first</offsets></td><td align="left"><offsets xml_i="15790" xml_f="15791" txt_i="10107" txt_f="10108">6</offsets></td><td align="left"><offsets xml_i="15813" xml_f="15817" txt_i="10109" txt_f="10113">-4.5</offsets></td><td align="left"><offsets xml_i="15839" xml_f="15842" txt_i="10114" txt_f="10117">1.5</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="15891" xml_f="15912" txt_i="10120" txt_f="10141">Intent to drink scale</offsets></td><td align="left"><offsets xml_i="15934" xml_f="15951" txt_i="10142" txt_f="10159">Cross Over effect</offsets></td><td align="left"><offsets xml_i="15973" xml_f="15986" txt_i="10160" txt_f="10173">Placebo first</offsets></td><td align="left"><offsets xml_i="16008" xml_f="16009" txt_i="10174" txt_f="10175">9</offsets></td><td align="left"><offsets xml_i="16031" xml_f="16035" txt_i="10176" txt_f="10180">-2.3</offsets></td><td align="left"><offsets xml_i="16057" xml_f="16060" txt_i="10181" txt_f="10184">4.5</offsets></td><td align="left"><offsets xml_i="16082" xml_f="16087" txt_i="10185" txt_f="10190">-0.63</offsets></td><td align="left"><offsets xml_i="16109" xml_f="16113" txt_i="10191" txt_f="10195">0.54</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="16162" xml_f="16179" txt_i="10198" txt_f="10215">Sumatriptan first</offsets></td><td align="left"><offsets xml_i="16201" xml_f="16202" txt_i="10216" txt_f="10217">6</offsets></td><td align="left"><offsets xml_i="16224" xml_f="16228" txt_i="10218" txt_f="10222">0.67</offsets></td><td align="left"><offsets xml_i="16250" xml_f="16253" txt_i="10223" txt_f="10226">1.7</offsets></td><td></td><td></td></tr><tr><td></td><td align="left"><offsets xml_i="16311" xml_f="16330" txt_i="10230" txt_f="10249">Linear Trend effect</offsets></td><td align="left"><offsets xml_i="16352" xml_f="16365" txt_i="10250" txt_f="10263">Placebo first</offsets></td><td align="left"><offsets xml_i="16387" xml_f="16388" txt_i="10264" txt_f="10265">9</offsets></td><td align="left"><offsets xml_i="16410" xml_f="16414" txt_i="10266" txt_f="10270">16.1</offsets></td><td align="left"><offsets xml_i="16436" xml_f="16439" txt_i="10271" txt_f="10274">7.9</offsets></td><td align="left"><offsets xml_i="16461" xml_f="16465" txt_i="10275" txt_f="10279">2.12</offsets></td><td align="left"><offsets xml_i="16487" xml_f="16492" txt_i="10280" txt_f="10285">0.058</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="16541" xml_f="16558" txt_i="10288" txt_f="10305">Sumatriptan first</offsets></td><td align="left"><offsets xml_i="16580" xml_f="16581" txt_i="10306" txt_f="10307">6</offsets></td><td align="left"><offsets xml_i="16603" xml_f="16608" txt_i="10308" txt_f="10313">-2.67</offsets></td><td align="left"><offsets xml_i="16630" xml_f="16633" txt_i="10314" txt_f="10317">4.0</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="16682" xml_f="16697" txt_i="10320" txt_f="10335">Sensation Scale</offsets></td><td align="left"><offsets xml_i="16719" xml_f="16736" txt_i="10336" txt_f="10353">Cross Over effect</offsets></td><td align="left"><offsets xml_i="16758" xml_f="16771" txt_i="10354" txt_f="10367">Placebo first</offsets></td><td align="left"><offsets xml_i="16793" xml_f="16794" txt_i="10368" txt_f="10369">9</offsets></td><td align="left"><offsets xml_i="16816" xml_f="16820" txt_i="10370" txt_f="10374">-6.6</offsets></td><td align="left"><offsets xml_i="16842" xml_f="16844" txt_i="10375" txt_f="10377">24</offsets></td><td align="left"><offsets xml_i="16866" xml_f="16871" txt_i="10378" txt_f="10383">-0.66</offsets></td><td align="left"><offsets xml_i="16893" xml_f="16897" txt_i="10384" txt_f="10388">0.52</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="16946" xml_f="16963" txt_i="10391" txt_f="10408">Sumatriptan first</offsets></td><td align="left"><offsets xml_i="16985" xml_f="16986" txt_i="10409" txt_f="10410">6</offsets></td><td align="left"><offsets xml_i="17008" xml_f="17010" txt_i="10411" txt_f="10413">11</offsets></td><td align="left"><offsets xml_i="17032" xml_f="17034" txt_i="10414" txt_f="10416">11</offsets></td><td></td><td></td></tr><tr><td></td><td align="left"><offsets xml_i="17092" xml_f="17111" txt_i="10420" txt_f="10439">Linear Trend effect</offsets></td><td align="left"><offsets xml_i="17133" xml_f="17146" txt_i="10440" txt_f="10453">Placebo first</offsets></td><td align="left"><offsets xml_i="17168" xml_f="17169" txt_i="10454" txt_f="10455">9</offsets></td><td align="left"><offsets xml_i="17191" xml_f="17195" txt_i="10456" txt_f="10460">-6.8</offsets></td><td align="left"><offsets xml_i="17217" xml_f="17219" txt_i="10461" txt_f="10463">21</offsets></td><td align="left"><offsets xml_i="17241" xml_f="17245" txt_i="10464" txt_f="10468">0.80</offsets></td><td align="left"><offsets xml_i="17267" xml_f="17271" txt_i="10469" txt_f="10473">0.44</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="17320" xml_f="17337" txt_i="10476" txt_f="10493">Sumatriptan first</offsets></td><td align="left"><offsets xml_i="17359" xml_f="17360" txt_i="10494" txt_f="10495">6</offsets></td><td align="left"><offsets xml_i="17382" xml_f="17387" txt_i="10496" txt_f="10501">-27.7</offsets></td><td align="left"><offsets xml_i="17409" xml_f="17411" txt_i="10502" txt_f="10504">15</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="17460" xml_f="17473" txt_i="10507" txt_f="10520">Craving Scale</offsets></td><td align="left"><offsets xml_i="17495" xml_f="17512" txt_i="10521" txt_f="10538">Cross Over effect</offsets></td><td align="left"><offsets xml_i="17534" xml_f="17547" txt_i="10539" txt_f="10552">Placebo first</offsets></td><td align="left"><offsets xml_i="17569" xml_f="17570" txt_i="10553" txt_f="10554">9</offsets></td><td align="left"><offsets xml_i="17592" xml_f="17596" txt_i="10555" txt_f="10559">-7.4</offsets></td><td align="left"><offsets xml_i="17618" xml_f="17621" txt_i="10560" txt_f="10563">4.2</offsets></td><td align="left"><offsets xml_i="17643" xml_f="17648" txt_i="10564" txt_f="10569">-1.92</offsets></td><td align="left"><offsets xml_i="17670" xml_f="17675" txt_i="10570" txt_f="10575">0.084</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="17724" xml_f="17741" txt_i="10578" txt_f="10595">Sumatriptan first</offsets></td><td align="left"><offsets xml_i="17763" xml_f="17764" txt_i="10596" txt_f="10597">6</offsets></td><td align="left"><offsets xml_i="17786" xml_f="17787" txt_i="10598" txt_f="10599">2</offsets></td><td align="left"><offsets xml_i="17809" xml_f="17812" txt_i="10600" txt_f="10603">2.4</offsets></td><td></td><td></td></tr><tr><td></td><td align="left"><offsets xml_i="17870" xml_f="17889" txt_i="10607" txt_f="10626">Linear Trend effect</offsets></td><td align="left"><offsets xml_i="17911" xml_f="17924" txt_i="10627" txt_f="10640">Placebo first</offsets></td><td align="left"><offsets xml_i="17946" xml_f="17947" txt_i="10641" txt_f="10642">9</offsets></td><td align="left"><offsets xml_i="17969" xml_f="17972" txt_i="10643" txt_f="10646">3.6</offsets></td><td align="left"><offsets xml_i="17994" xml_f="17997" txt_i="10647" txt_f="10650">5.9</offsets></td><td align="left"><offsets xml_i="18019" xml_f="18024" txt_i="10651" txt_f="10656">-0.37</offsets></td><td align="left"><offsets xml_i="18046" xml_f="18050" txt_i="10657" txt_f="10661">0.72</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="18099" xml_f="18116" txt_i="10664" txt_f="10681">Sumatriptan first</offsets></td><td align="left"><offsets xml_i="18138" xml_f="18139" txt_i="10682" txt_f="10683">6</offsets></td><td align="left"><offsets xml_i="18161" xml_f="18164" txt_i="10684" txt_f="10687">6.3</offsets></td><td align="left"><offsets xml_i="18186" xml_f="18189" txt_i="10688" txt_f="10691">4.2</offsets></td><td></td><td></td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label><offsets xml_i="18290" xml_f="18297" txt_i="10694" txt_f="10701">Table 2</offsets></label><caption><p><offsets xml_i="18317" xml_f="18378" txt_i="10701" txt_f="10762">Cross Over Effect – variable "Anxious" on Affect Analog Scale</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td></td><td align="center"><offsets xml_i="18477" xml_f="18482" txt_i="10765" txt_f="10770">Group</offsets></td><td align="center"><offsets xml_i="18506" xml_f="18507" txt_i="10771" txt_f="10772">N</offsets></td><td align="center"><offsets xml_i="18531" xml_f="18535" txt_i="10773" txt_f="10777">Mean</offsets></td><td align="center"><offsets xml_i="18559" xml_f="18566" txt_i="10778" txt_f="10785">SE Mean</offsets></td><td align="center"><offsets xml_i="18590" xml_f="18591" txt_i="10786" txt_f="10787">T</offsets></td><td align="center"><offsets xml_i="18615" xml_f="18616" txt_i="10788" txt_f="10789">p</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="18662" xml_f="18671" txt_i="10790" txt_f="10799">"Anxious"</offsets></td><td align="left"><offsets xml_i="18693" xml_f="18710" txt_i="10800" txt_f="10817">Cross-over effect</offsets></td><td align="left"><offsets xml_i="18732" xml_f="18745" txt_i="10818" txt_f="10831">Placebo first</offsets></td><td align="left"><offsets xml_i="18767" xml_f="18768" txt_i="10832" txt_f="10833">9</offsets></td><td align="left"><offsets xml_i="18790" xml_f="18795" txt_i="10834" txt_f="10839">-0.67</offsets></td><td align="left"><offsets xml_i="18817" xml_f="18821" txt_i="10840" txt_f="10844">0.33</offsets></td><td align="right"><offsets xml_i="18844" xml_f="18849" txt_i="10845" txt_f="10850">-2.36</offsets></td><td align="left"><offsets xml_i="18871" xml_f="18876" txt_i="10851" txt_f="10856">0.046</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="18925" xml_f="18942" txt_i="10859" txt_f="10876">Sumatriptan first</offsets></td><td align="left"><offsets xml_i="18964" xml_f="18965" txt_i="10877" txt_f="10878">6</offsets></td><td align="left"><offsets xml_i="18987" xml_f="18991" txt_i="10879" txt_f="10883">0.83</offsets></td><td align="left"><offsets xml_i="19013" xml_f="19017" txt_i="10884" txt_f="10888">0.54</offsets></td><td></td><td></td></tr></tbody></table></table-wrap><p><offsets xml_i="19077" xml_f="19618" txt_i="10891" txt_f="11432">On the intention to drink scale no significant mean effect was found. In the linear trend scores there is some evidence of a significant crossover effect (t = 2.12, p = 0.058, df = 11; exact permutation P = 0.075; Wilcoxon Rank Sum test P = 0.059). Further analysis showed that no significant difference in linear trend was found for the group that received sumatriptan first, but in the group that received placebo first, a marginally significant linear trend effect was noted (t = 2.039, two-sided p = 0.07, one-sided p = 0.04) (See table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="19650" xml_f="19651" txt_i="11432" txt_f="11433">3</offsets></xref><offsets xml_i="19658" xml_f="19659" txt_i="11433" txt_f="11434">)</offsets></p><table-wrap position="float" id="T3"><label><offsets xml_i="19707" xml_f="19714" txt_i="11435" txt_f="11442">Table 3</offsets></label><caption><p><offsets xml_i="19734" xml_f="19770" txt_i="11442" txt_f="11478">Linear Trend – Intent to Drink Scale</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td></td><td align="center"><offsets xml_i="19869" xml_f="19874" txt_i="11481" txt_f="11486">Group</offsets></td><td align="center"><offsets xml_i="19898" xml_f="19899" txt_i="11487" txt_f="11488">N</offsets></td><td align="center"><offsets xml_i="19923" xml_f="19927" txt_i="11489" txt_f="11493">Mean</offsets></td><td align="center"><offsets xml_i="19951" xml_f="19958" txt_i="11494" txt_f="11501">SE Mean</offsets></td><td align="center"><offsets xml_i="19982" xml_f="19983" txt_i="11502" txt_f="11503">T</offsets></td><td align="center"><offsets xml_i="20007" xml_f="20008" txt_i="11504" txt_f="11505">P</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="20054" xml_f="20069" txt_i="11506" txt_f="11521">Intent to drink</offsets></td><td align="left"><offsets xml_i="20091" xml_f="20110" txt_i="11522" txt_f="11541">Linear Trend effect</offsets></td><td align="left"><offsets xml_i="20132" xml_f="20145" txt_i="11542" txt_f="11555">Placebo first</offsets></td><td align="left"><offsets xml_i="20167" xml_f="20168" txt_i="11556" txt_f="11557">9</offsets></td><td align="left"><offsets xml_i="20190" xml_f="20194" txt_i="11558" txt_f="11562">16.1</offsets></td><td align="left"><offsets xml_i="20216" xml_f="20219" txt_i="11563" txt_f="11566">7.9</offsets></td><td align="left"><offsets xml_i="20241" xml_f="20246" txt_i="11567" txt_f="11572">2.039</offsets></td><td align="left"><offsets xml_i="20268" xml_f="20272" txt_i="11573" txt_f="11577">0.04</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="20321" xml_f="20338" txt_i="11580" txt_f="11597">Sumatriptan first</offsets></td><td align="left"><offsets xml_i="20360" xml_f="20361" txt_i="11598" txt_f="11599">6</offsets></td><td align="left"><offsets xml_i="20383" xml_f="20388" txt_i="11600" txt_f="11605">-2.67</offsets></td><td align="left"><offsets xml_i="20410" xml_f="20413" txt_i="11606" txt_f="11609">4.0</offsets></td><td align="left"><offsets xml_i="20435" xml_f="20440" txt_i="11610" txt_f="11615">-.066</offsets></td><td align="left"><offsets xml_i="20462" xml_f="20466" txt_i="11616" txt_f="11620">0.53</offsets></td></tr></tbody></table></table-wrap></sec><sec><title><offsets xml_i="20523" xml_f="20533" txt_i="11622" txt_f="11632">Discussion</offsets></title><p><offsets xml_i="20544" xml_f="21012" txt_i="11633" txt_f="12101">Our results show that overall sumatriptan has no significant ability to provoke alcohol lsymptoms or to cause a desire or craving for alcohol. The significant placebo effect on the variable "anxious" may merely represent normal anxiety when confronted with an unfamiliar task. This is made especially plausible by the fact that it only occurs in the group that took placebo first, suggesting that as patients become more familiar with the trial the anxiety disappears.</offsets></p><p><offsets xml_i="21019" xml_f="21607" txt_i="12102" txt_f="12690">The interpretation of the linear trend on the intention to drink scale in patients who received placebo first is more difficult. On its own this suggests that sumatriptan did cause changes not seen with placebo. However, if this was true, one would also expect to find a significant linear trend in the group who received sumatriptan first. Furthermore, a significant overall drug effect should have been found. It is more plausible that the trend found is due either to error introduced by the small group size and multiple tests, or by factors unrelated to sumatriptan within the group.</offsets></p><p><offsets xml_i="21614" xml_f="21931" txt_i="12691" txt_f="13008">The general lack of efficacy of sumatriptan in producing alcohol-like symptoms or a desire to drink alcohol may suggest that the 5HT1D receptor plays little role in the pathophysiology of alcoholism. This is in contrast to studies that show decreased GH response to sumatriptan administration in abstinent alcoholics.</offsets></p><p><offsets xml_i="21938" xml_f="22204" txt_i="13009" txt_f="13275">However, several limiting factors must be borne in mind. Firstly, the sample size was small and consisted of recently detoxified alcoholics. Chronic use of alcohol may alter the neurochemical milieu and provide a false picture of receptor involvement in alcoholism [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="22235" xml_f="22236" txt_i="13275" txt_f="13276">1</offsets></xref><offsets xml_i="22243" xml_f="22245" txt_i="13276" txt_f="13278">].</offsets></p><p><offsets xml_i="22252" xml_f="22553" txt_i="13279" txt_f="13580">Secondly, sumatriptan has poor penetration of the blood-brain barrier, and its failure to provoke a response may be a result of this, rather than lack of involvement of the 5HT1D receptor in the pathogenesis of alcoholism. However, given that previous work has shown hormonal (in alcohol dependence) [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="22585" xml_f="22587" txt_i="13580" txt_f="13582">12</offsets></xref><offsets xml_i="22594" xml_f="22595" txt_i="13582" txt_f="13583">,</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="22627" xml_f="22629" txt_i="13583" txt_f="13585">13</offsets></xref><offsets xml_i="22636" xml_f="22673" txt_i="13585" txt_f="13622">]and behavioural (in OCD) responses [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="22705" xml_f="22707" txt_i="13622" txt_f="13624">15</offsets></xref><offsets xml_i="22714" xml_f="22737" txt_i="13624" txt_f="13647">], this is less likely.</offsets></p><p><offsets xml_i="22744" xml_f="23345" txt_i="13648" txt_f="14249">Furthermore, it may be that GH response to sumatriptan does not necessarily correlate with behavioural changes. In OCD, there have been conflicting reports about symptom exacerbation following sumatriptan challenges, yet a decreased GH response is observed. It is possible that GH release is mediated via different pathways to behavioural effects. This is suggested by the finding in autism, where increased GH release correlated with severity of repetitive behaviours. As both OCD and alcohol dependence can be conceptualized as repetitive behaviours, this contrasts with findings in these disorders.</offsets></p><p><offsets xml_i="23352" xml_f="23492" txt_i="14250" txt_f="14387">Finally, the majority of the sample (11 patients) had late onset alcohol dependence (age of onset &gt; 25) using the von Knorring criteria [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="23524" xml_f="23526" txt_i="14387" txt_f="14389">19</offsets></xref><offsets xml_i="23533" xml_f="23550" txt_i="14389" txt_f="14406">]. George et al [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="23582" xml_f="23584" txt_i="14406" txt_f="14408">20</offsets></xref><offsets xml_i="23591" xml_f="23779" txt_i="14408" txt_f="14596">] found ethanol -like responses to mCPP were only found in the early onset group. It is possible that we did not observe a response in our sample as most had late onset alcohol dependence.</offsets></p></sec><sec><title><offsets xml_i="23801" xml_f="23811" txt_i="14598" txt_f="14608">Conclusion</offsets></title><p><offsets xml_i="23822" xml_f="24235" txt_i="14609" txt_f="15022">While our study suggests that the 5HT1D receptor does not play a significant role in the pathogenesis of alcoholism, further studies with sumatriptan and with agents that have better blood-brain barrier penetration are needed in both alcohol dependant and non-alcohol dependent samples to consolidate this finding. Stratification of further samples into early and late onset alcohol dependence may also be of use.</offsets></p></sec><sec><title><offsets xml_i="24257" xml_f="24276" txt_i="15024" txt_f="15043">Competing interests</offsets></title><p><offsets xml_i="24287" xml_f="24347" txt_i="15044" txt_f="15104">The author(s) declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="24369" xml_f="24391" txt_i="15106" txt_f="15128">Authors' contributions</offsets></title><p><offsets xml_i="24402" xml_f="24774" txt_i="15129" txt_f="15501">BV participated in the statistical analysis and prepared the manuscript for publication. CJH participated in the study design and carried out the patient ratings. WP participated in the preparation of the manuscript. JSM performed the statistical analysis. DJS conceived of the study, participated in the study design and participated in the preparation of the manuscript.</offsets></p></sec><sec><title><offsets xml_i="24796" xml_f="24819" txt_i="15503" txt_f="15526">Pre-publication history</offsets></title><p><offsets xml_i="24830" xml_f="24894" txt_i="15527" txt_f="15591">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-244X/5/31/prepub"></ext-link></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The authors would like to thank Mimi Roberts for her help in patient recruitment. Bavanisha Vythilingum, Charmaine Hugo and Dan Stein are supported by the Medical Research Council of South Africa.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>LeMarquand</surname><given-names>D</given-names></name><name><surname>Pihl</surname><given-names>RO</given-names></name><name><surname>Benkelfat</surname><given-names>C</given-names></name></person-group><article-title>Serotonin and alcohol intake, abuse, and dependence: clinical evidence</article-title><source>Biological Psychiatry</source><year>1994</year><volume>36</volume><fpage>326</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">7993959</pub-id><pub-id pub-id-type="doi">10.1016/0006-3223(94)90630-0</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>LeMarquand</surname><given-names>D</given-names></name><name><surname>Pihl</surname><given-names>RO</given-names></name><name><surname>Benkelfat</surname><given-names>C</given-names></name></person-group><article-title>Serotonin and alcohol intake, abuse, and dependence: findings of animal studies</article-title><source>Biological psychiatry</source><year>1994</year><volume>36</volume><fpage>395</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">7803601</pub-id><pub-id pub-id-type="doi">10.1016/0006-3223(94)91215-7</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verheul</surname><given-names>R</given-names></name><name><surname>van den Brink</surname><given-names>W</given-names></name><name><surname>Geerlings</surname><given-names>P</given-names></name></person-group><article-title>A three-pathway psychobiological model of craving for alcohol</article-title><source>Alcohol Alcohol</source><year>1999</year><volume>34</volume><fpage>197</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">10344781</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>C</given-names></name><name><surname>Stamford</surname><given-names>JA</given-names></name></person-group><article-title>Evidence that 5-hydroxytryptamine release in rat dorsal raphe nucleus is controlled by 5-HT1A, 5-HT1B and 5-HT1D autoreceptors</article-title><source>Br J Pharmacol</source><year>1995</year><volume>114</volume><fpage>1107</fpage><lpage>1109</lpage><pub-id pub-id-type="pmid">7620698</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benkelfat</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>DL</given-names></name><name><surname>Hill</surname><given-names>JL</given-names></name><name><surname>George</surname><given-names>DT</given-names></name><name><surname>Nutt</surname><given-names>D</given-names></name><name><surname>Linnoila</surname><given-names>M</given-names></name></person-group><article-title>Ethanol-like properties of the serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients</article-title><source>Archives of General Psychiatry</source><year>1991</year><volume>48</volume><fpage>333</fpage><pub-id pub-id-type="pmid">1672588</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>Webb</surname><given-names>E</given-names></name><name><surname>Cooney</surname><given-names>N</given-names></name><name><surname>Kranzler</surname><given-names>HR</given-names></name><name><surname>Charney</surname><given-names>DS</given-names></name></person-group><article-title>Specificity of ethanol-like effects elicited by serotonergic and noradrenergic mechanisms</article-title><source>Archives of General Psychiatry</source><year>1994</year><volume>51</volume><fpage>898</fpage><lpage>911</lpage><pub-id pub-id-type="pmid">7944878</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Signs</surname><given-names>SA</given-names></name><name><surname>Schechter</surname><given-names>MD</given-names></name></person-group><article-title>The role of dopamine and serotonin receptors in the mediation of the ethanol interoceptive cue</article-title><source>Pharmacol Biochem Behav</source><year>1988</year><volume>30</volume><fpage>55</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">3174755</pub-id><pub-id pub-id-type="doi">10.1016/0091-3057(88)90424-8</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naranjo</surname><given-names>CA</given-names></name><name><surname>Sullivan</surname><given-names>JT</given-names></name><name><surname>Kadlec</surname><given-names>KE</given-names></name><name><surname>Woodley-Remus</surname><given-names>DV</given-names></name><name><surname>Kennedy</surname><given-names>G</given-names></name><name><surname>Sellers</surname><given-names>EM</given-names></name></person-group><article-title>Differential effects of viqualine on alcohol intake and other consummatory behaviors</article-title><source>Clin Pharmacol Ther</source><year>1989</year><volume>46</volume><fpage>301</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">2673621</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naranjo</surname><given-names>CA</given-names></name><name><surname>Kadlec</surname><given-names>KE</given-names></name><name><surname>Sanhueza</surname><given-names>P</given-names></name><name><surname>Woodley-Remus</surname><given-names>D</given-names></name><name><surname>Sellers</surname><given-names>EM</given-names></name></person-group><article-title>Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers</article-title><source>Clin Pharmacol Ther</source><year>1990</year><volume>47</volume><fpage>490</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">2328557</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naranjo</surname><given-names>CA</given-names></name><name><surname>Poulos</surname><given-names>CX</given-names></name><name><surname>Bremner</surname><given-names>KE</given-names></name><name><surname>Lanctot</surname><given-names>KL</given-names></name></person-group><article-title>Fluoxetine attenuates alcohol intake and desire to drink</article-title><source>Int Clin Psychopharmacol</source><year>1994</year><volume>9</volume><fpage>163</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">7814825</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naranjo</surname><given-names>CA</given-names></name><name><surname>Poulos</surname><given-names>CX</given-names></name><name><surname>Bremner</surname><given-names>KE</given-names></name><name><surname>Lanctot</surname><given-names>KL</given-names></name></person-group><article-title>Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependentdrinkers</article-title><source>Clin Pharmacol Ther</source><year>1992</year><volume>51</volume><fpage>729</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">1535302</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vescovi</surname><given-names>PP</given-names></name><name><surname>Coiro</surname><given-names>V</given-names></name></person-group><article-title>Persistence of defective serotonergic and GABAergic controls of growth hormone secretion in long-term abstinent alcoholics</article-title><source>Alcohol Alcohol</source><year>1997</year><volume>32</volume><fpage>85</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">9131896</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coiro</surname><given-names>V</given-names></name><name><surname>Vescovi</surname><given-names>PP</given-names></name></person-group><article-title>Alcoholism abolishes the growth hormone response to sumatriptan administration in man</article-title><source>Metabolism</source><year>1995</year><volume>44</volume><fpage>1577</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">8786727</pub-id><pub-id pub-id-type="doi">10.1016/0026-0495(95)90078-0</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Novotny</surname><given-names>S</given-names></name><name><surname>Hollander</surname><given-names>E</given-names></name><name><surname>Phillips</surname><given-names>A</given-names></name><name><surname>Allen</surname><given-names>A</given-names></name><name><surname>Wasserman</surname><given-names>S</given-names></name><name><surname>Iyengar</surname><given-names>R</given-names></name></person-group><article-title>Increased repetitive behaviours and prolactin responsivity to oral m-chlorophenylpiperazine in adults with autism spectrum disorders</article-title><source>Int J Neuropsychopharmacol</source><year>2004</year><volume>7</volume><fpage>249</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">15132762</pub-id><pub-id pub-id-type="doi">10.1017/S146114570400433X</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>DJ</given-names></name><name><surname>Van Heerden</surname><given-names>B</given-names></name><name><surname>Wessels</surname><given-names>CJ</given-names></name><name><surname>Van Kradenburg</surname><given-names>J</given-names></name><name><surname>Warwick</surname><given-names>J</given-names></name><name><surname>Wasserman</surname><given-names>HJ</given-names></name></person-group><article-title>Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive compulsive disorder : investigating the functional role of the serotonin auto-receptor</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>1999</year><volume>23</volume><fpage>1079</fpage><lpage>1099</lpage><pub-id pub-id-type="pmid">10621951</pub-id><pub-id pub-id-type="doi">10.1016/S0278-5846(99)00051-2</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maisto</surname><given-names>SA</given-names></name><name><surname>Connors</surname><given-names>GJ</given-names></name><name><surname>Tucker</surname><given-names>JA</given-names></name><name><surname>McCollam</surname><given-names>JB</given-names></name><name><surname>Adesso</surname><given-names>VJ</given-names></name></person-group><article-title>Validation of the sensation scale: a measure of subjective physiological responses to alcohol</article-title><source>Behav Res Ther</source><year>1980</year><volume>18</volume><fpage>37</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">7369986</pub-id><pub-id pub-id-type="doi">10.1016/0005-7967(80)90067-4</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hollander</surname><given-names>E</given-names></name><name><surname>Stein</surname><given-names>DJ</given-names></name><name><surname>DeCaria</surname><given-names>CM</given-names></name><name><surname>Cohen</surname><given-names>L</given-names></name><name><surname>Saoud</surname><given-names>JB</given-names></name><name><surname>Skodol</surname><given-names>AE</given-names></name><name><surname>Kellman</surname><given-names>D</given-names></name><name><surname>Rosnick</surname><given-names>L</given-names></name><name><surname>Oldham</surname><given-names>JM</given-names></name></person-group><article-title>Serotonergic sensitivity in borderline personality disorder :preliminary findings</article-title><source>American Journal of Psychiatry</source><year>1994</year><volume>151</volume><fpage>277</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">8296905</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bohn</surname><given-names>MJ</given-names></name><name><surname>Krahn</surname><given-names>DD</given-names></name><name><surname>Staehler</surname><given-names>BA</given-names></name></person-group><article-title>Development and initial validation of a measure of drinking urges in abstinent alcoholics</article-title><source>Alcoholism, Clinical and Experimental Research</source><year>1995</year><volume>19</volume><fpage>600</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7573780</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>von Knorring</surname><given-names>A-L</given-names></name><name><surname>Bohman</surname><given-names>M</given-names></name><name><surname>von Knorring</surname><given-names>L</given-names></name><name><surname>Oreland</surname><given-names>L</given-names></name></person-group><article-title>Platelet MAO activity as a biological marker in subgroups of alcoholism</article-title><source>Acta Psychiatr Scand</source><year>1985</year><volume>72</volume><fpage>51</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">4036659</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>DT</given-names></name><name><surname>Benkelfat</surname><given-names>C</given-names></name><name><surname>Rawlings</surname><given-names>RR</given-names></name><name><surname>Eckardt</surname><given-names>MJ</given-names></name><name><surname>Phillips</surname><given-names>MJ</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Wynne</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>DL</given-names></name><name><surname>Linnoila</surname><given-names>M</given-names></name></person-group><article-title>Behavioral and neuroendocrine responsesto mchlorophenylpiperazine in subtypes of alcoholics and in healthy comparisonsubjects</article-title><source>Am J Psychiatry</source><year>1997</year><volume>154</volume><fpage>81</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8988963</pub-id></citation></ref></ref-list></back></article>